Mifamurtide injection--Basic introduction to Mepact

Mifamurtide injection (mifamurtide) is an immunomodulatory drug used to treat osteosarcoma. It is developed and produced by Takeda France SAS (Takeda France SAS). The drug was approved for marketing by the European Union on March 6, 2009, but has not yet been approved in China and the United States. Its main indication is the postoperative adjuvant treatment of high-grade, resectable, non-metastatic osteosarcoma in children, adolescents and young adults (2-30 years old), which needs to be used in combination with multi-agent chemotherapy. Clinical studies have confirmed that the drug has clear safety and effectiveness in patients aged 2 to 30 years old.

From the perspective of its mechanism of action, mivamutin is a fully synthetic cholecystyl dipeptide (MDP) derivative, and its design is inspired by the cell wall components of Mycobacterium. As a liposomal formulation, it targets the activation of macrophages and monocytes in the body via intravenous infusion. The drug is a specific ligand for the NOD2 receptor and can stimulate immune cells to produce a variety of cytokines, including tumor necrosis factor (TNF-α), interleukin (IL-1β, IL-6, IL-8 and IL-12), etc. These cytokines can not only enhance the body's immune response, but also directly kill tumor cells. In vitro experiments have shown that monocytes activated by mivamutin have a killing effect on a variety of tumor cells (such as melanoma, ovarian cancer, etc.), but have no obvious toxicity to normal cells.

In terms of clinical use, mivamutin injection has strict usage specifications. The recommended dose is 2mg/m²body surface area, administered intravenously, with each infusion lasting 1 hour. The standard treatment plan is divided into two phases: 12weeks of administration 2 times (with an interval of at least 3 days), and then 24weeks is changed to 1times per week. The entire course of treatment totals 36 weeks and 48 administrations need to be completed. The medicine needs to be stored at 2-8℃Store under refrigerated conditions, avoiding freezing and light. The reconstituted medicinal solution must be used within 6 hours, and the storage temperature must not exceed 25℃.

In terms of efficacy, mivamutide is used as an adjuvant postoperative treatment drug and can significantly improve the disease-free survival rate of patients when used in combination with chemotherapy. It activates the body's immune system and enhances its ability to clear residual tumor cells, thereby reducing the risk of recurrence. Clinical observations show that the most common adverse reactions during treatment with this drug include fever, chills, fatigue, nausea, etc. These reactions are mostly related to immune activation and are usually mild and controllable. It is worth noting that patients with respiratory diseases, cardiovascular diseases, or autoimmune diseases need to be particularly cautious, and relevant indicators need to be closely monitored during treatment. Overall, mivamutide provides a new treatment option for patients with osteosarcoma, but its use must be carried out under the strict guidance of professional doctors.

Reference link: https://www.ema.europa.eu/en/documents/product-information/mepact-epar-product-information_en.pdf